ClinicalTrials.gg
Not yet recruitingNCT07104110Updated Aug 5, 2025

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

A Phase 1/2 interventional study of QLH12016 and abiraterone acetate in Prostatic Neoplasms, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.

02

Conditions studied

  • Prostatic Neoplasms

Browse trials for

03

In context

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed the form.
  • Male, aged ≥ 18 years.
  • ≥ 3 months.
  • or cytologically confirmed prostate adenocarcinoma.
  • prostate cancer.
  • Organ function meet protocol requirements.
  • Recovered from all reversible AEs related to previous anticancer treatments.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with the following drugs:

    1. AR PROTAC class drugs.
    2. Other systemic anticancer therapy within 3 weeks or 5 half-lives prior to the first administration of the study treatment.
    3. Taditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first administration of the study treatment.
    4. Drugs that may cause drug-drug interactions (DDI) with the study treatment.
    5. Drugs known to prolong the or potentially cause torsades de pointes ventricular tachycardia
  • Presence of central nervous system , , or spinal cord compression.
  • Radiation therapy involving more than 25% of bone marrow within 4 weeks prior to the first administration of the medicinal product; local radiation therapy within 2 weeks prior to the first administration of the investigational medicinal product.
  • Treatment with other investigational drugs or major surgery within 4 weeks.
  • Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption.
  • With severe cardiovascular or cerebrovascular diseases or related history.
  • Active, uncontrolled infections.
  • History of other significant within 5 years.
  • Moderate to severe pulmonary disease significantly affecting lung function.
  • According to the investigator's judgment, there are comorbidities that seriously endanger subject safety or affect the subject's ability to complete the study.
  • Allergy to any of the investigational medicinal products or their components.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    QLH12016+NHA

    Drug: QLH12016 · Drug: abiraterone acetate · Drug: enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. The number of subjects with adverse events/serious adverse events (Phase Ib)

    Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline

    Time frame: Throughout phase Ib (approximately 1 year)

  2. The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol (Phase Ib)

    A DLT occurs during Cycle 1 (the DLT assessment period) that is assessed as related to study treatment.

    Time frame: From first dose of study treatment until the end of Cycle 1.

  3. Recommended phase II dose (RP2D) (Phase Ib)

    RP2D will be selected upon safety, PK and efficacy data.

    Time frame: Throughout phase Ib (approximately 1 year)

  4. Objective Response Rate (ORR) (Phase II)

    Best response until progression, as defined by RECIST 1.1 and PCWG3

    Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year)

  5. Objective Response Rate (ORR) (Phase II)

    Proportion of subjects with ≥ 50% PSA decrease

    Time frame: From time of Informed Consent to confirmed progressive disease (approximately 1 year).

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2027, 24 months later.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 24 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartEst.
Oct 2025
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07104110
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Oct 2025 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Aug 5, 2025

Study contacts

Wanhai Xu, PHD
Contact
xuwanhai@163.com
0451-86605612

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLH12016

Start the discussion